Adaptimmune Therapeutics PLC (ADAP)
1.10
-0.03
(-2.65%)
USD |
NASDAQ |
May 07, 16:00
1.10
0.00 (0.00%)
After-Hours: 16:08
Adaptimmune Therapeutics Revenue (Quarterly): 0.231M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.231M |
| September 30, 2023 | 7.319M |
| June 30, 2023 | 5.13M |
| March 31, 2023 | 47.60M |
| December 31, 2022 | 11.03M |
| September 30, 2022 | 7.007M |
| June 30, 2022 | 5.538M |
| March 31, 2022 | 3.575M |
| December 31, 2021 | 1.417M |
| September 30, 2021 | 1.203M |
| June 30, 2021 | 3.095M |
| March 31, 2021 | 0.434M |
| December 31, 2020 | 1.502M |
| September 30, 2020 | 1.193M |
| June 30, 2020 | 0.502M |
| March 31, 2020 | 0.761M |
| December 31, 2019 | 0.728M |
| September 30, 2019 | 0.237M |
| Date | Value |
|---|---|
| June 30, 2019 | 0.157M |
| March 31, 2019 | |
| December 31, 2018 | 1.479M |
| September 30, 2018 | 40.79M |
| June 30, 2018 | 9.038M |
| March 31, 2018 | 8.196M |
| December 31, 2017 | 4.27M |
| September 30, 2017 | 27.18M |
| June 30, 2017 | 3.521M |
| March 31, 2017 | 2.857M |
| December 31, 2016 | 8.536M |
| September 30, 2016 | 2.416M |
| June 30, 2016 | 0.328M |
| March 31, 2016 | 2.918M |
| September 30, 2015 | 3.940M |
| December 31, 2014 | 2.268M |
| September 30, 2014 | 1.533M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.157M
Minimum
Jun 2019
47.60M
Maximum
Mar 2023
5.192M
Average
1.417M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -47.92M |
| Total Expenses (Quarterly) | 50.09M |
| EPS Diluted (Quarterly) | -0.18 |
| Enterprise Value | 131.97M |
| Profit Margin (Quarterly) | -20.74K% |
| Earnings Yield | -43.07% |
| Normalized Earnings Yield | -51.29 |